[SCHEDULE 13G] BriaCell Therapeutics Corp. SEC Filing

Rhea-AI Filing Summary

Schedule 13G filed by Jeremy Myung Jae Plambeck reports his beneficial ownership in BriaCell Therapeutics Corp. The filing lists 4,329.72 directly held common shares, 29,956 BCTXW warrants (reported as 2,995.6 common-share equivalents at a 10:1 exercise ratio) and 63,132.88 BCTXZ rights (reported as 6,313.29 common-share equivalents at a 10:1 conversion ratio). The filing states an aggregate ownership equal to 100.0% of the class and provides detailed vote/disposition powers for the same share counts. The filer notes delays in registry updates: conversions for BCTXZ were not reflected until 09/05/2025 and for BCTXW until 09/11/2025. The statement includes a certification that the securities are not held to change control.

Positive

• Full disclosure of positions with precise counts for shares, warrants, and rights
• Certification of passive intent clarifies securities were not acquired to change control
• Detailed conversion ratios (10:1) and converted-equivalent counts are provided

Negative

• Inconsistent aggregate totals appear in the filing text (13,338.61 v. 13,638.61) which may confuse investors
• Transfer-agent/registry timing delays for BCTXZ and BCTXW conversions could temporarily misstate public records

Insights

Equity Ownership Analyst

Holder reports full class-level economic exposure via shares, warrants and rights.

The filing documents direct ownership of 4,329.72 common shares plus warrant and right positions convertible at a 10:1 ratio into an additional 2,995.6 and 6,313.29 common-share equivalents respectively, yielding the reported class percentage of 100.0%. The record includes explicit counts for voting and dispositive power matching these totals.

Registry timing differences are disclosed, with BCTXZ updates not reflected until 09/05/2025 and BCTXW until 09/11/2025, which could affect public registers and transfer agent records in the short term. Monitor formal transfer-agent confirmations and any subsequent amended filings within weeks for reconciled share counts.

Compliance & Filings Specialist

Filing is structured as a passive Schedule 13G with a certification of non-control intent.

The signer checked the filing under Schedule 13G conventions and included the required certification that the securities were not acquired to influence control. The statement lists address, citizenship and signature dated 10/10/2025 consistent with filing requirements.

Because the document discloses out-of-sync registry updates, investors and registrars should watch for any amendments or clarifying statements; administrative corrections or an amended 13G could appear within the next reporting cycle if counts change.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BriaCell Therapeutics Corp.

(Name of Issuer)

13G

(Title of Class of Securities)

10778Y104

(CUSIP Number)

08/25/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 10778Y104

1

Names of Reporting Persons

Plambeck Jeremy Myung Jae

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

KANSAS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,329.72
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,329.72
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,338.61

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

100.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Includes (i) 4,329.72 common shares, (ii) 2,695.6 common shares issuable upon exercise of 26,956 currently exercisable warrants (10:1 exercise ratio), and (iii) 6,313.29 common shares issuable upon conversion of 63,132.88 currently exercisable rights (10:1 conversion ratio).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BriaCell Therapeutics Corp.
(b)	Address of issuer's principal executive offices: Suite 300 1281 West Georgia Street, VANCOUVER, BRITISH COLUMBIA, CANADA, V6E 3J7
Item 2.
(a)	Name of person filing: Jeremy Myung Jae Plambeck
(b)	Address or principal business office or, if none, residence: 3448 Treesmill Dr. Manhattan, KS 66503 United States
(c)	Citizenship: United States
(d)	Title of class of securities: 13G
(e)	CUSIP No.: 10778Y104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: BCTX common shares = 4,329.719 BCTXW warrants (10for 1) = 29,956 warrants divided by 10 = 2,995.6 common shares BCTXZ rights (10 for 1) = 63,132.88 right divided by 10 = 6,313.29 common shares Total aggregate beneficial ownership: 4,329.72+2,995.6+6,313.29 = 13,638.61 common shares However, after emailing BriaCell Investor relations and Fidelity Investors and ComputerShare US and ComputerShare Canada, changes to warrants BCTXZ were not updates until September 5 for 10 to 1 conversion for 1 common share and for BCTXW 10 to 1 until September 11, 2025.
(b)	Percent of class: 100%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: BCTX common shares = 4,329.719 BCTXW warrants (10for 1) = 29,956 warrants divided by 10 = 2,995.6 common shares BCTXZ rights (10 for 1) = 63,132.88 right divided by 10 = 6,313.29 common shares Total aggregate beneficial ownership: 4,329.72+2,995.6+6,313.29 = 13,638.61 common shares However, after emailing BriaCell Investor relations and Fidelity Investors and ComputerShare US and ComputerShare Canada, changes to warrants BCTXZ were not updates until September 5 for 10 to 1 conversion for 1 common share and for BCTXW 10 to 1 until September 11, 2025.
	(ii) Shared power to vote or to direct the vote: BCTX common shares = 4,329.719 BCTXW warrants (10for 1) = 29,956 warrants divided by 10 = 2,995.6 common shares BCTXZ rights (10 for 1) = 63,132.88 right divided by 10 = 6,313.29 common shares Total aggregate beneficial ownership: 4,329.72+2,995.6+6,313.29 = 13,638.61 common shares However, after emailing BriaCell Investor relations and Fidelity Investors and ComputerShare US and ComputerShare Canada, changes to warrants BCTXZ were not updates until September 5 for 10 to 1 conversion for 1 common share and for BCTXW 10 to 1 until September 11, 2025.
	(iii) Sole power to dispose or to direct the disposition of: BCTX common shares = 4,329.719 BCTXW warrants (10for 1) = 29,956 warrants divided by 10 = 2,995.6 common shares BCTXZ rights (10 for 1) = 63,132.88 right divided by 10 = 6,313.29 common shares Total aggregate beneficial ownership: 4,329.72+2,995.6+6,313.29 = 13,638.61 common shares However, after emailing BriaCell Investor relations and Fidelity Investors and ComputerShare US and ComputerShare Canada, changes to warrants BCTXZ were not updates until September 5 for 10 to 1 conversion for 1 common share and for BCTXW 10 to 1 until September 11, 2025.
	(iv) Shared power to dispose or to direct the disposition of: BCTX common shares = 4,329.719 BCTXW warrants (10for 1) = 29,956 warrants divided by 10 = 2,995.6 common shares BCTXZ rights (10 for 1) = 63,132.88 right divided by 10 = 6,313.29 common shares Total aggregate beneficial ownership: 4,329.72+2,995.6+6,313.29 = 13,638.61 common shares However, after emailing BriaCell Investor relations and Fidelity Investors and ComputerShare US and ComputerShare Canada, changes to warrants BCTXZ were not updates until September 5 for 10 to 1 conversion for 1 common share and for BCTXW 10 to 1 until September 11, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Plambeck Jeremy Myung Jae

Signature:	Jeremy Myung Jae Plambeck
Name/Title:	Mr.
Date:	10/10/2025

FAQ

What does the Schedule 13G filed for BCTX state about ownership?

The filer reports 4,329.72 direct common shares plus 29,956 BCTXW warrants (counted as 2,995.6 common equivalents) and 63,132.88 BCTXZ rights (counted as 6,313.29 common equivalents), and states an aggregate ownership of 100.0% of the class.

Does the filer claim control of BriaCell (BCTX)?

No. The filing includes a certification that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of the issuer.

Were any conversion or registry timing issues disclosed in the BCTX filing?

Yes. The filer notes conversion updates for BCTXZ were not reflected until 09/05/2025 and for BCTXW until 09/11/2025 on transfer-agent records.

What conversion ratio is used for BCTX warrants and rights in the filing?

Both BCTXW warrants and BCTXZ rights are reported using a 10:1 conversion/exercise ratio (ten instruments converting to one common share equivalent).

Who signed the Schedule 13G for BriaCell (BCTX)?

The filing is signed by Jeremy Myung Jae Plambeck with a signature date of 10/10/2025.